https://www.urologytimes.com/watch 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-60-year-old-man-with-prostate-cancer 2022-07-18 0.50 https://www.urologytimes.com/case-based-peer-perspectives/optimizing-sequential-therapy-in-metastatic-castration-resistant-prostate-cancer-mcrpc-with-bone 2025-01-22 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-72-year-old-man-with-metastatic-urothelial-carcinoma-and-a-76-year-old-man-with-locally 2023-10-19 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-75-year-old-woman-with-high-risk-muscle-invasive-bladder-cancer 2022-02-07 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-66-year-old-man-with-prostate-cancer-and-a-78-year-old-man-with-metastatic-prostate-cancer 2023-09-22 0.50 https://www.urologytimes.com/case-based-peer-perspectives/case-based-peer-perspectives-a-65-year-old-man-diagnosed-with-psma-positive-mcrpc 2024-09-20 0.50 https://www.urologytimes.com/case-based-peer-perspectives/65-year-old-and-77-year-old-men-with-prostate-cancer 2022-12-22 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-64-year-old-man-with-elevated-psa-levels 2022-04-21 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-64-year-old-man-with-metastatic-prostate-cancer 2022-05-23 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-70-year-old-man-diagnosed-with-psma-positive-mcrpc 2024-10-08 0.50 https://www.urologytimes.com/case-based-peer-perspectives/navigating-treatment-decisions-in-metastatic-hormone-sensitive-prostate-cancer-mhspc 2025-06-09 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-74-year-old-man-with-metastatic-prostate-cancer 2022-12-14 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-66-year-old-man-with-metastatic-prostate-cancer 2022-08-09 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-67-year-old-man-with-metastatic-prostate-cancer 2023-01-18 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-74-year-old-man-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-a-62-year-old-man 2025-06-23 0.50 https://www.urologytimes.com/case-based-peer-perspectives/a-60-year-old-woman-with-muscle-invasive-bladder-cancer-and-a-77-year-old-man-with-muscle 2022-12-21 0.50 https://www.urologytimes.com/investigator-perspectives/insights-into-doublet-therapy-and-clinical-trial-takeaways-for-metastatic-prostate-cancer 2025-06-23 0.50 https://www.urologytimes.com/investigator-perspectives/advancing-perioperative-therapy-in-muscle-invasive-bladder-cancer 2025-10-31 0.50 https://www.urologytimes.com/investigator-perspectives/optimizing-therapy-for-high-risk-biochemically-recurrent-prostate-cancer 2025-10-23 0.50 https://www.urologytimes.com/investigator-perspectives/shifting-the-standard-early-clinical-data-on-innovative-bladder-sparing-strategies-in-nmibc 2025-07-28 0.50 https://www.urologytimes.com/investigator-perspectives/genetic-testing-in-prostate-cancer-evidence-from-real-world-data-on-decipher 2023-05-23 0.50 https://www.urologytimes.com/investigator-perspectives/innovative-immunological-and-target-therapies-for-nmibc-recent-clinical-trial-data 2024-05-29 0.50 https://www.urologytimes.com/investigator-perspectives/high-risk-non-muscle-invasive-bladder-cancer-recent-updates-to-keynote-057-trial-data 2023-06-07 0.50 https://www.urologytimes.com/investigator-perspectives/pten-deficiency-and-treatment-optimization-in-mhspc 2026-02-23 0.50 https://www.urologytimes.com/investigator-perspectives/the-prognostic-power-of-psa-what-ultra-low-levels-reveal-in-mhspc 2025-05-02 0.50 https://www.urologytimes.com/investigator-perspectives/treatment-advances-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer 2023-12-12 0.50 https://www.urologytimes.com/investigator-perspectives/treatment-outcomes-in-black-patients-with-mhspc-new-data-and-insights 2025-06-23 0.50 https://www.urologytimes.com/investigator-perspectives/enhanced-detection-in-prostate-cancer-the-promise-of-64cu-sar-bispsma-for-improved-imaging-and 2024-09-10 0.50 https://www.urologytimes.com/investigator-perspectives/advancing-long-term-outcomes-in-bcg-unresponsive-nmibc 2026-07-21 0.50 https://www.urologytimes.com/investigator-perspectives/clinical-impact-of-next-generation-androgen-receptor-inhibition-in-mhspc 2026-05-26 0.50 https://www.urologytimes.com/investigator-perspectives/the-role-of-rectal-spacers-in-the-treatment-of-prostate-cancer 2023-11-01 0.50 https://www.urologytimes.com/investigator-perspectives/rethinking-comparisons-novel-strategies-for-evaluating-androgen-receptor-inhibitors-in-prostate 2025-04-07 0.50 https://www.urologytimes.com/peer-exchange/emerging-therapeutic-approaches-in-high-and-intermediate-risk-nmibc 2024-01-05 0.50 https://www.urologytimes.com/peer-exchange/evolving-role-of-biomarkers-in-prostate-cancer 2024-06-25 0.50 https://www.urologytimes.com/peer-exchange/the-role-of-fusion-guided-biopsy-in-the-management-of-prostate-cancer 2024-05-21 0.50 https://www.urologytimes.com/peer-exchange/advances-in-psma-targeted-pet-imaging-for-prostate-cancer 2022-11-07 0.50 https://www.urologytimes.com/peer-exchange/emerging-therapies-for-high-risk-non-muscle-invasive-bladder-cancer 2025-11-18 0.50 https://www.urologytimes.com/peer-exchange/translating-real-world-evidence-into-practice-optimizing-systemic-therapy-selection-in-mcspc 2025-10-28 0.50 https://www.urologytimes.com/peer-exchange/multidisciplinary-perspectives-on-oral-androgen-deprivation-therapies-in-advanced-prostate-cancer 2026-01-27 0.50 https://www.urologytimes.com/peer-exchange/key-updates-in-nmibc-emerging-insights-on-oncolytic-immunotherapies 2025-05-30 0.50 https://www.urologytimes.com/peer-exchange/long-term-management-of-metastatic-castration-sensitive-prostate-cancer-with-androgen-receptor 2025-11-24 0.50 https://www.urologytimes.com/peer-exchange/management-of-advanced-prostate-cancer-in-urology-update-on-androgen-receptor-inhibitors 2021-11-30 0.50 https://www.urologytimes.com/peer-exchange/emerging-treatments-for-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer 2024-05-23 0.50 https://www.urologytimes.com/peer-exchange/psma-pet-imaging-for-prostate-cancer-recent-advances-and-key-updates 2023-05-22 0.50 https://www.urologytimes.com/peer-exchange/optimizing-treatment-intensification-in-metastatic-castration-sensitive-prostate-cancer-evidence 2026-03-12 0.50 https://www.urologytimes.com/peer-exchange/rectal-spacers-revolutionizing-prostate-cancer-treatment 2023-11-29 0.50 https://www.urologytimes.com/peer-exchange/from-past-challenges-to-current-innovations-in-treatment-of-nmibc 2025-02-28 0.50 https://www.urologytimes.com/peer-exchange/understanding-androgen-receptor-pathway-inhibitors-in-metastatic-castration-sensitive-prostate 2026-06-24 0.50 https://www.urologytimes.com/peer-exchange/the-nmibc-treatment-landscape-emerging-evidence-and-real-world-impact 2025-06-09 0.50 https://www.urologytimes.com/peer-exchange/advances-in-imaging-for-prostate-cancer-the-role-for-psma-pet-imaging 2024-05-21 0.50 https://www.urologytimes.com/peer-exchange/immunotherapies-in-treatment-of-bladder-cancer 2022-02-08 0.50 https://www.urologytimes.com/peer-exchange/esmo-2023-immunotherapy-advancements-in-bladder-cancer 2023-12-14 0.50 https://www.urologytimes.com/peer-exchange/advancing-the-treatment-paradigm-for-mcrpc-insights-into-combination-therapy-and-future 2025-06-09 0.50 https://www.urologytimes.com/peer-exchange/practice-management-in-prostate-cancer-key-challenges-and-practical-solutions 2023-07-25 0.50 https://www.urologytimes.com/peer-exchange/exploring-treatments-for-metastatic-castration-sensitive-prostate-cancer 2024-10-23 0.50 https://www.urologytimes.com/peer-exchange/integrating-the-perioperative-sandwich-approach-in-muscle-invasive-bladder-cancer 2026-05-27 0.50 https://www.urologytimes.com/peer-exchange/patient-centric-care-approach-in-the-management-of-overactive-bladder-oab 2024-02-01 0.50 https://www.urologytimes.com/peer-exchange/advancements-and-insights-in-non-muscle-invasive-bladder-cancer-emerging-pd-1-pd-l1-inhibitors 2024-12-18 0.50 https://www.urologytimes.com/peer-exchange/new-directions-in-the-treatment-of-non-muscle-invasive-bladder-cancer 2025-01-28 0.50 https://www.urologytimes.com/peer-exchange/understanding-patients-and-clinical-management-of-oab 2021-04-28 0.50 https://www.urologytimes.com/peer-exchange/patient-and-provider-education-on-overactive-bladder 2021-04-28 0.50 https://www.urologytimes.com/peer-exchange/efficacy-and-safety-of-therapy-for-overactive-bladder 2021-04-28 0.50 https://www.urologytimes.com/peer-exchange/evolving-treatment-approaches-advanced-prostate-cancer 2021-04-28 0.50 https://www.urologytimes.com/peers-and-perspectives/androgen-receptor-targeted-therapies-in-metastatic-castration-resistant-prostate-cancer 2024-08-16 0.50 https://www.urologytimes.com/peers-and-perspectives/clinical-updates-on-psma-pet-imaging-for-prostate-cancer 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/emerging-treatment-strategies-in-advanced-prostate-cancer-the-role-for-arpis 2024-06-20 0.50 https://www.urologytimes.com/peers-and-perspectives/transforming-advanced-prostate-cancer-care-through-personalized-immunotherapy-and-real-world 2025-11-10 0.50 https://www.urologytimes.com/peers-and-perspectives/deep-data-dive-highlights-from-asco-2024-on-the-treatment-of-high-risk-bcg-unresponsive-nmibc 2024-07-30 0.50 https://www.urologytimes.com/peers-and-perspectives/advancements-in-imaging-and-diagnosing-kidney-cancers-the-future-role-of-pet-imaging-agents 2025-05-12 0.50 https://www.urologytimes.com/peers-and-perspectives/urology-practice-management-considerations-and-treatment-selection-for-special-populations 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/advances-in-imaging-and-diagnosing-kidney-cancers-the-emerging-role-of-pet-imaging-agents 2024-06-18 0.50 https://www.urologytimes.com/peers-and-perspectives/optimizing-androgen-deprivation-therapy-in-prostate-cancer-evidence-best-practices-and-new 2025-06-09 0.50 https://www.urologytimes.com/peers-and-perspectives/treatment-of-overactive-bladder 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/the-role-of-androgen-receptor-inhibitors-in-the-management-of-advanced-prostate-cancer 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/the-evolving-role-of-irp-monitoring-in-the-treatment-and-management-of-urinary-stones 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/fast-acting-flexible-and-focused-modern-approaches-to-adt-in-prostate-cancer 2025-07-22 0.50 https://www.urologytimes.com/peers-and-perspectives/improving-outcomes-in-advanced-prostate-cancer-with-rectal-spacers-through-a-multidisciplinary 2025-12-12 0.50 https://www.urologytimes.com/peers-and-perspectives/evolving-perspectives-on-diagnostic-imaging-in-advanced-prostate-cancer 2026-03-10 0.50 https://www.urologytimes.com/peers-and-perspectives/innovative-immunological-and-target-therapies-for-nmibc-recent-clinical-trial-data-shaping-the 2025-01-28 0.50 https://www.urologytimes.com/peers-and-perspectives/18f-fluciclovine-versus-68ga-psma-11-imaging-for-prostate-cancer-biochemical-recurrence 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/gallium-68-psma-targeted-pet-imaging-in-prostate-cancer-staging-and-outcomes 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/the-role-of-liquid-biomarker-for-early-detection-of-prostate-cancer 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/refining-prostate-cancer-risk-stratification-with-structure-based-biomarkers-and-imaging-tools 2025-10-13 0.50 https://www.urologytimes.com/peers-and-perspectives/a-collaborative-approach-to-the-treatment-and-management-of-advanced-prostate-cancer 2024-06-24 0.50 https://www.urologytimes.com/peers-and-perspectives/genetic-testing-in-prostate-cancer 2024-06-24 0.50 https://www.urologytimes.com/virtual-tumor-board/beyond-bcg-tumor-board-insights-on-managing-unresponsive-nmibc-with-novel-treatments 2025-05-13 0.50 https://www.urologytimes.com/virtual-tumor-board/exploring-treatment-approaches-for-advanced-prostate-cancer 2024-11-26 0.50 https://www.urologytimes.com/virtual-tumor-board/practice-updates-in-prostate-cancer-imaging 2022-03-24 0.50 https://www.urologytimes.com/virtual-tumor-board/psma-pet-imaging-and-prostate-cancer 2024-02-17 0.50 https://www.urologytimes.com/virtual-tumor-board/navigating-low-grade-intermediate-risk-nmibc-real-world-cases-and-expert-insights 2025-08-12 0.50 https://www.urologytimes.com/virtual-tumor-board/personalizing-care-for-patients-with-advanced-prostate-cancer 2026-06-19 0.50 https://www.urologytimes.com/urology-medical-perspectives/bcg-immunotherapy-strategies-in-bcg-naive-nmibc 2025-07-29 0.50 https://www.urologytimes.com/urology-medical-perspectives/emerging-clinical-trials-within-nmibc 2025-03-04 0.50 https://www.urologytimes.com/urology-medical-perspectives/advancements-in-targeting-the-androgen-receptor-pathway-in-metastatic-prostate-cancer 2024-04-25 0.50 https://www.urologytimes.com/urology-medical-perspectives/the-role-of-perirectal-spacers-in-the-treatment-of-prostate-cancer 2023-06-30 0.50 https://www.urologytimes.com/urology-medical-perspectives/intravesical-drug-delivery-strategies-for-nmibc 2026-02-28 0.50 https://www.urologytimes.com/urology-medical-perspectives/psma-pet-and-the-evolving-imaging-paradigm-in-prostate-cancer 2024-01-30 0.50 https://www.urologytimes.com/urology-medical-perspectives/evolving-treatment-paradigms-in-high-risk-nmibc 2025-11-25 0.50 https://www.urologytimes.com/urology-medical-perspectives/clinical-use-of-onabotulinumtoxina-for-overactive-bladder 2025-03-04 0.50 https://www.urologytimes.com/urology-medical-perspectives/the-evolving-treatment-landscape-of-low-grade-upper-tract-urothelial-carcinoma 2022-08-18 0.50 https://www.urologytimes.com/urology-medical-perspectives/clinical-use-of-micronized-abiraterone-for-patients-with-prostate-cancer 2023-08-22 0.50 https://www.urologytimes.com/urology-medical-perspectives/overview-of-advanced-metastatic-prostate-cancer 2023-11-15 0.50 https://www.urologytimes.com/urology-medical-perspectives/expert-perspectives-on-advanced-metastatic-prostate-cancer 2022-06-29 0.50 https://www.urologytimes.com/urology-medical-perspectives/immunotherapy-strategies-across-bladder-cancer-continuum 2025-10-08 0.50 https://www.urologytimes.com/urology-medical-perspectives/multidisciplinary-perspectives-on-high-risk-nmibc 2026-07-15 0.50 https://www.urologytimes.com/urology-medical-perspectives/the-evolving-paradigm-of-prostate-cancer-imaging-and-new-modalities 2023-12-20 0.50 https://www.urologytimes.com/podcasts/pearls-perspectives-with-amy-pearlman 2026-01-29 0.50 https://www.urologytimes.com/podcasts/uroonc-minute-with-adam-weiner 2026-01-08 0.50 https://www.urologytimes.com/podcasts/first-assist-with-taylor-goodstein 2025-10-03 0.50 https://www.urologytimes.com/podcasts/expert-approach-with-joy-maulik 2026-01-23 0.50 https://www.urologytimes.com/podcasts/speaking-of-urology 2026-01-29 0.50 https://www.urologytimes.com/special-report/the-detection-gap-identifying-cis-in-non-muscle-invasive-bladder-cancer 2026-05-08 0.50 https://www.urologytimes.com/special-report/news-network-bladder-cancer-at-asco-gu-2026 2026-02-23 0.50 https://www.urologytimes.com/special-report/perioperative-treatment-in-mibc-when-to-refer-and-what-to-expect 2026-07-14 0.50 https://www.urologytimes.com/special-report/rx-review-integrating-novel-gemcitabine-intravesical-system-into-nmibc-care 2025-09-26 0.50 https://www.urologytimes.com/special-report/news-network-prostate-cancer-at-aua-2026 2026-05-12 0.50 https://www.urologytimes.com/special-report/the-estradiol-initiative-rethinking-adt-for-prostate-cancer 2026-01-12 0.50 https://www.urologytimes.com/special-report/urology-times-news-network-lugpa-2025 2025-11-07 0.50 https://www.urologytimes.com/special-report/community-insights-on-treating-high-risk-nmibc 2026-08-18 0.50 https://www.urologytimes.com/special-report/rethinking-adt-ai-biomarkers-in-intermediate-risk-prostate-cancer 2026-06-09 0.50 https://www.urologytimes.com/special-report/news-network-bladder-cancer-at-suo-2025 2025-12-02 0.50 https://www.urologytimes.com/special-report/external-validation-of-a-post-rp-multimodal-ai-prognostic-model 2026-05-18 0.50 https://www.urologytimes.com/special-report/news-network-prostate-cancer-at-suo-2025 2025-12-02 0.50 https://www.urologytimes.com/special-report/inside-the-suction-revolution-devices-data-and-outcomes-in-endourology 2025-11-26 0.50 https://www.urologytimes.com/special-report/pten-testing-and-akt-inhibition-practical-guidance-in-prostate-cancer 2026-07-21 0.50 https://www.urologytimes.com/special-report/urology-times-news-network-esmo-2025 2025-11-07 0.50 https://www.urologytimes.com/special-report/onabotulinumtoxina-in-oab-optimizing-persistence-with-fewer-sites 2026-06-10 0.50 https://www.urologytimes.com/special-report/rx-review-advancing-bladder-cancer-care-exploring-subcutaneous-immunotherapy 2025-10-10 0.50 https://www.urologytimes.com/special-report/special-report-screening-diagnosis-and-treatment-of-prostate-cancer 2025-07-02 0.50 https://www.urologytimes.com/special-report/rx-review-mitomycin-approval-for-lg-ir-nmibc 2025-07-02 0.50